1
|
Pérez-Galán P, Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Wiestner A, Bezombes C, Balasubramanian S, Chiu C, Doshi P. ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO
AND IN VIVO
MODELS OF B-CELL NON-HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_29] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | | | | | - C. Rossi
- Hematology-Oncology; Centre de Recherche en Cancérologie de Toulouse (CRCT); Toulouse France
| | - G. Roué
- Hemato-Oncology; IDIBAPS; Barcelona Spain
| | | | - E. Giné
- Hematology; Hospital Clínic-IDIBAPS; Barcelona Spain
| | - E. Campo
- Hematophathology; Hospital Clínic-IDIBAPS; Barcelona Spain
| | - D. Colomer
- Hematophathology; Hospital Clínic-IDIBAPS; Barcelona Spain
| | - A. Wiestner
- Hematology Branch; National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda Maryland USA
| | - C. Bezombes
- Hematology-Oncology; Centre de Recherche en Cancérologie de Toulouse (CRCT); Toulouse France
| | | | - C. Chiu
- Oncology; Janssen R&D, Spring House; Pennsylvania USA
| | - P. Doshi
- Oncology; Janssen R&D, Spring House; Pennsylvania USA
| |
Collapse
|
2
|
López-Guerra M, Xargay-Torrent S, Rosich L, Montraveta A, Roldán J, Matas-Céspedes A, Villamor N, Aymerich M, López-Otín C, Pérez-Galán P, Roué G, Campo E, Colomer D. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia 2014; 29:96-106. [PMID: 24781018 DOI: 10.1038/leu.2014.143] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2013] [Revised: 04/10/2014] [Accepted: 04/14/2014] [Indexed: 02/06/2023]
Abstract
Targeting Notch signaling has emerged as a promising therapeutic strategy for chronic lymphocytic leukemia (CLL), especially for the poor prognostic subgroup of NOTCH1-mutated patients. Here, we report that the γ-secretase inhibitor PF-03084014 inhibits the constitutive Notch activation and induces selective apoptosis in CLL cells carrying NOTCH1 mutations. Combination of PF-03084014 with fludarabine has a synergistic antileukemic effect in primary NOTCH1-mutated CLL cells, even in the presence of the protective stroma. At transcriptional level, PF-03084014 plus fludarabine treatment induces the upregulation of the proapoptotic gene HRK and the downmodulation of MMP9, IL32 and RAC2 genes that are related to invasion and chemotaxis. PF-03084014 also overcomes fludarabine-mediated activation of nuclear factor-κB signaling. Moreover, this combination impairs angiogenesis and CXCL12-induced responses in NOTCH1-mutated CLL cells, in particular those related to tumoral migration and invasion. Importantly, all these collaborative effects are specific for NOTCH1 mutation and do not occur in unmutated cases. In conclusion, we provide evidence that Notch is a therapeutic target in CLL cases with NOTCH1-activating mutations, supporting the use of Notch pathway inhibitors in combination with chemotherapy as a promising approach for the treatment of these high-risk CLL patients.
Collapse
Affiliation(s)
- M López-Guerra
- Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - S Xargay-Torrent
- Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - L Rosich
- Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - A Montraveta
- Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - J Roldán
- Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - A Matas-Céspedes
- Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - N Villamor
- Hematopathology Unit, Department of Pathology, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - M Aymerich
- Hematopathology Unit, Department of Pathology, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - C López-Otín
- Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo - IUOPA, Oviedo, Spain
| | - P Pérez-Galán
- Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - G Roué
- Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - E Campo
- Hematopathology Unit, Department of Pathology, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - D Colomer
- 1] Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain [2] Hematopathology Unit, Department of Pathology, Hospital Clínic, University of Barcelona, Barcelona, Spain
| |
Collapse
|